Published in final edited form as:

Int Immunopharmacol. 2011 July ; 11(7): 853–858. doi:10.1016/j.intimp.2011.01.030.

MDSC as a Mechanism of Tumor Escape from Sunitinib Mediated Anti-Angiogenic Therapy

James Finke¹, Jennifer Ko^{1,2}, Brian Rini³, Pat Rayman¹, Joanna Ireland¹, and Peter Cohen⁴

¹Department of Immunology, Cleveland Clinic

²Department of Immunology Pathology, Cleveland Clinic

³Department of Solid Tumor, Cleveland Clinic

⁴Department of Mayo Clinic Arizona, Cleveland Clinic

Abstract

Sunitinib is a receptor tyrosine kinase inhibitor (TKI) that is front-line therapy for metastatic renal cell carcinoma (mRCC). Its antitumor activity is related to its ability to block tumor cell and tumor vasculature cell signaling via several TKI receptors (i.e. vascular endothelial growth factor receptors VEGFRs, platelet-derived growth factors (PDGFs), stem cell factors). Sunitinib also targets myeloid derived suppressor cells (MDSCs) significantly reducing their accumulation in the peripheral blood and reversing T cell (IFN γ) suppression in both mRCC patients and in murine tumor models. This reduction in immune suppression provides a rationale for combining sunitinib with immunotherapy for the treatment of certain tumor types. Despite these encouraging findings, however, we have observed that sunitinib has variable impact at reducing MDSCs and restoring T cell function within the tumor microenvironment. Given the immunosuppressive and proangiogenic activities of MDSC, it seems plausible that their persistence may contribute to the resistance that develops in sunitinib-treated patients. While sunitinib reduced tumor infiltrating MDSCs in Renca and CT26-bearing mice, coinciding with strong to modest decreases in tumor size respectively, it was ineffective at 'reducing MDSCs (<35% reduction in Gr1+CD11b+) or tumor burden in 4T1-bearing mice. Persistence of intratumor MDSCs was paralleled by depressed intratumor T cell IFN γ response and increased GM-CSF expression. Additionally, *in vitro* and *in vivo* experiments showed that GM-CSF prolongs survival of MDSCs, thus protecting them from the effects of sunitinib via a pSTAT5-dependent pathway. Although preliminary, there is evidence of intratumor MDSC resistance in some mRCC patients following sunitinib treatment. Intratumor MDSC persistence and T cell IFN γ response post nephrectomy in patients receiving sunitinib in a neoadjuvant setting is being compared to RCC patients undergoing nephrectomy without prior sunitinib treatment. Tumors from untreated patients showed suppressed T cell IFN γ response along with substantial expression of MDSCs (5% of total digested cells). Thus far, tumors from 5/8 neoadjuvant patients showed persistence of intratumor MDSCs and low T cell IFN γ production post sunitinib treatment, findings that parallel results from untreated tumors. In the remaining 3 neoadjuvant patients, intratumor MDSCs were detected at low levels which coincided with a T cell IFN γ response similar to that observed with normal donor peripheral T cells. GM-CSF's role in promoting MDSC survival in patient tumors is supported by the observation that

© 2010 Elsevier B.V. All rights reserved.

Corresponding Author: James Finke PhD, Department Immunology, NE40, Professor of Molecular Medicine, Cleveland Clinic College of Medicine of CWRU, Cleveland Clinic, Cleveland, OH 44195.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

GM-CSF is produced in short-term RCC cultures at levels capable of protecting MDSCs from sunitinib-induced cell death. Additionally, persistence of MDSC also may be associated with increased expression of proangiogenic proteins, such as MMP9, MMP8, and IL-8 produced by tumor stromal cells or infiltrating MDSCs. Indeed our findings suggest that the most dominate MDSC subset in RCC patients is the neutrophilic population that produces proangiogenic proteins. We propose that the development of sunitinib resistance is partly mediated by the survival of MDSCs intratumorally, thereby providing sustained immune suppression and angiogenesis.

Introduction

Targeting angiogenesis as a treatment for cancer is an approach with demonstrated utility in some tumor types including mRCC (1,2). The pathogenesis of clear -cell RCC is partly the result of a common inactivation of the von Hippel-Lindau gene resulting in the overexpression of VEGF which promotes tumor-associated angiogenesis and tumor growth (3). Small molecule inhibitors that target the VEGF signaling pathway have demonstrated activity in mRCC. One such inhibitor, sunitinib, currently front-line treatment for mRCC produces a 50% response rate and can improve progression-free survival when compared to IFN α (2). Sunitinib is a multitargeted TKI that blocks signaling via VEGFRs, Flt3, stem cell factors (c-Kit), PDGFs, and colony-stimulating factor-1 receptors (CM-CSFRs) (4). Sunitinib's major activity is thought to be based on its inhibition of endothelial cells in the tumor vasculature, hence it was once hypothesized that resistance would be limited due to the drug's targeting of genetically stable, non transformed cells. (5,6). However, sunitinib may also impair growth and viability of RCC tumor cells(7).

Despite the significant improvement in treatment, mRCC patients ultimately develop resistance to sunitinib, via multiple proposed mechanisms that are still under investigation. There is growing evidence that MDSCs which accumulate in human and murine tumors, may play an important role in the general process of angiogenesis. VEGF, along with other tumor-derived products, blocks myeloid cell differentiation resulting in the accumulation of a heterogeneous group of immature myeloid cells (8-11). Co-injection of murine tumors with MDSC (Gr1+CD11b+) increased intratumoral vascular density, reduced necrosis, and augmented tumor growth (12,13). MDSCs produce high levels of MMP9, which can function as an angiogenic switch during tumorigenesis and MDSCs from MMP9 knockout mice have a significant reduction in their tumor promoting activity (13). Additional studies suggest that MDSCs represent a mechanism of resistance to anti-VEGF antibody treatment in mouse tumor models (14,15). MDSCs from resistant murine tumors when added to sensitive tumors could confer resistance to anti-VEGF antibody therapy. As such, combination anti-VEGF, anti-MDSC antibody therapy inhibited the growth of refractory tumors compared to anti-VEGF alone (16,17).

Hence, in addition to their obstruction of effective immunotherapy (9,16,17), MDSC may also obstruct anti-angiogenic therapy. This manuscript summarizes our findings that suggest MDSCs contribute to sunitinib resistance in human cancer patients as a consequence of MDSC protective cytokines that are expressed within the tumor microenvironment of relatively resistant tumors .

Materials and Methods

Human subjects

Peripheral blood (PB) was collected from metastatic RCC patients (clear-cell histology) receiving sunitinib as monotherapy (50 mg p.o. daily, for 28 days followed by 14 days of rest, comprising one cycle of therapy), from sunitinib neoadjuvant RCC patients and age-

matched normal healthy donors (18-20). Tumor tissue (clear-cell histology) was obtained from surgical pathology at Cleveland Clinic Foundation (CCF). All donors provided IRB-approved informed consent.

Peripheral blood mononuclear cell (PBMC) isolation

Blood was drawn in heparin containing collection tubes and processed within two hours. PBMCs were isolated by subjecting blood to Ficoll Hypaque density centrifugation as previously described (18-20). Cells were either used fresh or were frozen and maintained in liquid nitrogen. For phenotypic and functional studies, all time points for an individual patient were thawed together and used in the same experiment.

Mouse tumor models

Experiments were performed under institutionally approved animal research committee protocols adhering to United States Department of Agriculture (USDA) guidelines. Female BALB/c mice from NCI, Frederick, Maryland, were maintained pathogen-free (USDA) and studied at 8-12 wks. 4T1-mammary, CT26-colonic, and RENCA-renal carcinomas syngeneic to BALB/c mice maintained and injected into mice as previously described (19). For some experiments, mice were treated with sunitinib 4, 20, or 40 mg/kg/day i.p. for 9 days total (19). Intraperitoneal treatment yielded the same MDSC reductions as oral treatment. Spleens, bone marrow (BM), and tumors were processed as previously described (19). (STAT5ab (null/null) and wild type (WT) BM was obtained as previously described (19).

MDSC Analysis

MDSCs were analyzed from the PB and tumors of RCC patients. Surface staining for HLA-DR, CD15, CD14, and CD33 followed Fc block (human IgG at RT) for 30 min at 4°C as described (19,20). Samples were acquired on a BD FACSCalibur and analyzed using CellQuest software

Murine MDSCs from spleen, BM and tumors were surface stained (CD11b and Gr1) as previously described. Intracellular staining of BM MDSCs for expression of pSTAT3 and pSTAT5 was performed as previously detailed (19).

In some experiments, MDSC subsets were isolated from human RCC tissue for analysis of expression of proangiogenic proteins by proteome profile array (PPA). After RCC tumors were digested, as previously described, the cells were stained with antibodies to CD33, HLA-Dr, CD14, and CD15. The cells were sorted using a FACSCalibur into CD33⁺HLA-Dr⁻CD15⁺CD14⁻ (n-MDSC), CD33⁺HLA-Dr⁻CD15⁻CD14⁻ (lin neg-MDSC), and CD33⁺HLA-Dr⁻CD15⁻CD14⁺ (m-MDSC) subsets. Lysates were then made from the subsets, protein assays performed and equal amounts of protein used in a PPA (R&D Systems)(20).

Analysis of T cell IFN γ production and T cell proliferation

Human PBMCs were stimulated with anti-CD3/CD28 antibodies and IL-2. At the end of 72 hours, Golgi plug was added to cells for 6 hours, and then the cells were harvested and stained for FACS analysis. Surface staining of CD3 and CD4 was followed by intracellular staining for cytokines IFN γ and IL-4 (20).

Intracellular IFN γ was detected in murine spleen cells stimulated with anti-CD3/anti-CD28 for 72 hrs followed by FACS staining for IFN γ and CD3 as described previously. Proliferation was assayed with either CFSE dilutions or tritiated thymidine incorporation as described (19).

Human Tumors

RCC tissue was digested with collagenase, DNase, and hyaluronidase (Sigma) for 30 min and sieve-filtered to obtain a single-cell suspension. A portion of cells were stained for MDSC and T cell function. Fourteen RCC were cultured short-term (1-2 passages) and GM-CSF was quantified in the resultant cell-free supernatants, or in supernatants derived from the long-term, clear-cell RCC line, SK-RC26b, (previously acquired from Dr. Neil Bander at Cornell Medical Center) in the presence or absence of sunitinib.

Analysis of growth factors and proangiogenic proteins

Cell-free tumor-conditioned media (TCM) from sunitinib-treated and untreated tumor cells were frozen at -80°C and semiquantitative analysis of numerous cytokines, chemokines, and growth factors was done according to the human cytokine and angiogenesis proteome profile arrays (RnD Systems). Analysis was done using NIH image J software. For quantitative analysis of GM-CSF, plasma was assayed according to the Bio-Plex Pro custom assay (Biorad). Tissue lysates were brought to 1mg/mL using 1xPBS with 0.5% BSA, and 50uL added to each well. A separate, standard curve was made using lysis buffer as diluent for the analysis of cell lysates. Data was acquired and analyzed on a Luminex device using the Biorad Bio-Plex System and Bio-Plex Manager 3.0 software.

Biostatistics

Murine experiments, results were pooled from $n \geq 3$ and mean $\pm$ standard deviation expressed. Treatment groups were compared using a t-test for two samples assuming equal variances. p-value < 0.05 was deemed significant. Statistical analysis of human MDSCs, T cells and clinical correlates was performed as described previously (19,20).

Experimental Results and Discussion

Sunitinib reduces splenic MDSC levels, restores T cell function, and can enhance the efficacy of immunotherapy in sunitinib-sensitive murine tumor models

Our findings using three mouse tumor models showed that sunitinib reduced MDSC levels and improved T cell responses systemically (19). When mice bearing Renca (renal cancer), CT26 (colon cancer) and 4T1 (mammary tumor) were treated i.p. for 9 days with sunitinib (20 and 40 mg/kg) a highly significant reduction in splenic MDSC (Gr1+CD11b+) occurred to a similar degree in all three tumor models resulting in restoration of T cell type-1 IFN γ and proliferative T cell responses to normal levels observed with T cells from naïve non-tumor bearing (NTB) mice. The contribution of MDSCs to T cell suppression in tumor bearing mice was evident by the restoration of T cell function following mechanical MDSC depletion (anti-Gr1Ab) and by near total suppression conferred to naïve T cells when tumor-bearing splenic MDSC were added to activation cultures.

Similar findings have been reported by others. Indeed, sunitinib monotherapy was shown to reduce MDSC levels in a number of transplantable tumors but with variable impact on growth (7,19,21). Sunitinib also delayed the onset of tumor induction and reduced the incidence and growth of tumors in a mouse mammary tumor transgenic model (22). This reduction in MDSC was accompanied by the restoration of T cell function as evident by an improved T cell IFN γ response (7,19,21)(Table 1). The reduction of MDSC in sunitinib treated TBM may partly account for its ability to reduce T-regulatory cell levels since MDSCs are known to induce T reg cells (CD4+CD25hi+Foxp3+)(7,18,19,21).

The reduction in splenic T cell suppression by sunitinib suggests that in some mouse models sunitinib may improve the efficacy of immunotherapy. Indeed, it was shown that sunitinib treatment of mice implanted with the B16-MO5 tumor significantly enhanced the

therapeutic activity of a DC-based vaccine (23). When compared to either sunitinib or vaccine alone, treatment with the combination caused a greater reduction in tumor volume and significantly produced long term survivors. Combinational therapy induced a reduction in peripheral and intratumor MDSC and T reg frequencies and the therapeutic benefit correlated with augmented vaccine-induced CD8⁺ TIL frequencies (tetramer) (23). These findings complement those of Ozao-Choy et al, who showed that in the MCA26 tumor model, combining sunitinib with adenoviral mIL-12 plus 41BB ligand significantly enhanced survival over any other combinations (21). Additionally, sunitinib, when combined with adoptively transferred T cells, improved their *in vivo* expansion and antitumor activity (24). While these results suggest that sunitinib may improve the efficacy of immunotherapy, additional studies are needed to increase the therapeutic effectiveness of such combinations and to address the impact of combinational therapy in tumors where resistance to sunitinib exists.

Intratumoral MDS selectively persist in a sunitinib-resistant tumor model (4T1), in a GM-CSF and pSTAT5 manner

Our previous work has shown sunitinib to variably effects on tumor growth in a tumor-model depend way. Renca (renal) tumors were very sensitive to sunitinib (20 and 40 mg/kg) while CT26 tumors (colon carcinoma) progressed, but at a slower rate. However, in the 4T1 model (mammary tumor) 40/mg/kg of sunitinib had minimal effect on tumor growth. The analysis of MDSCs revealed that, in contrast to splenic MDSCs, which were significantly reduced in all 3 tumor models, there was a variable reduction in intratumoral MDSC levels depending on the tumor model. While sunitinib significantly reduced tumor infiltrating MDSCs in Renca (83%) and CT26 (64%) bearing mice, it was much less effective at reducing MDSCs in the 4T1 model (<36% reduction in Gr1+CD11b+). Persistence of MDSC in the 4T1 tumors post sunitinib treatment was paralleled by depressed T cell IFN γ response (4.8+/-0.8% n=15) compared to that of splenic T cells (25.2 +/- 4.9%) (19).

The persistence of intratumor MDSCs in the sunitinib-resistant 4T1 model may be related to local production of GM-CSF. A PPA, followed by the quantitative Luminex assay, revealed that GM-CSF was selectively expressed in tumor tissue lysates but not in plasma from 4T1 TB mice, mirroring the resistance pattern of MDSCs in 4T1-bearing mice. Moreover, the sunitinib sensitivity of intratumoral MDSCs from Renca and CT26 TB mice coincided with low levels of GM-CSF in the tumor relative to 4T1 tumors. Additional studies with purified cytokines demonstrated that GM-CSF (1-10 ng/ml) was most effective at protecting BM-derived MDSC from the anti-proliferative and proapoptotic effects of sunitinib (1 μ g/ml) (19). Importantly, administration of recombinant murine GM-CSF along with sunitinib to 4T1 bearing mice could partially render the normally susceptible splenic MDSCs resistant to sunitinib treatment and this coincided with diminished T cell production of IFN γ .

Additional studies aimed at defining the mechanism responsible for GM-CSF-mediated sunitinib resistance suggested involvement of pSTAT5 (19). Others have shown that STAT3 activation in tumors and MDSCs promotes immune suppression and that sunitinib can inhibit STAT3 leading to tumor apoptosis and MDSC reduction (7,25). Likewise, our studies showed that pSTAT3-promoting BM derived MDSC cultures (IL-6 and G-CSF) remained sensitive to sunitinib-mediated suppression. In contrast, pSTAT5-promoting MDSC cultures driven with GM-CSF (19,26) showed sunitinib-resistance *in vitro*. pSTAT5's involvement in GM-CSF-mediated MDSC protection was supported by the observation that STAT5ab (null/null) BM-derived MDSCs compared to WT BM-derived MDSCs were not protected from sunitinib-mediated apoptosis in the presence of GM-CSF.. Thus, we propose that the presence of GM-CSF promotes MDSC resistance to sunitinib by providing an alternating signaling pathway which both sustains MDSC viability, and

remains unaltered in the presence of sunitinib. The precise downstream events involved in this resistance are yet to be defined.

Sunitinib treatment of RCC patients reduces PB MDSCs and increases T cell function

In cancer patients, MDSCs have been defined as CD33+CD11b+ HLADR⁻ cells, although this population is heterogeneous based on morphology and surface staining (27). MDSCs in the PB of RCC patients (CD33+HLADR⁻) constitute 5.3% (+/-1.0;n=50) of the mononuclear cell population compared to 0.99% (+/-0.29;n=11) in healthy age matched donors. An analysis of tumors from untreated (no sunitinib) RCC patients showed that MDSCs comprise 5.9+/-1.1%(n=38) of the total tumor single cell suspension (Ko et al unpublished). We find that there are at least three MDSC populations in the blood and tumor. The neutrophilic population (n-MDSC, CD15+CD33+HLADR⁻) is the most abundant (56% of MDSC), followed by the lineage-negative subset (lin-MDSC;40%) with only a few monocytic MDSCs (m-MDSC CD14+CD33+HLADR⁻, 5%) detected (19,20). These findings are consistent with other studies showing that the granulocytic CD15+ MDSC subset is dominant in RCC patients (28-30). In addition, this MDSC subset displays several markers (i.e. CD66b) that are also expressed on N-formyl-methionyl-leucyl-phenylalanine (FMLP)-activated, but not resting neutrophils (29,31) (Ko, et al., manuscript in preparation). The increase in MDSC frequency is associated with decreased IFN γ production by PB T cells (n=49, p $\leq$ 0.001) and tumor infiltrating T cells (n=23, p $\leq$ 0.001) stimulated with anti-CD3/anti-CD28 antibodies relative to the response of healthy donor T cells (20) (Finke, et al., unpublished). The contribution of n-MDSCs to T cell suppression in RCC patients is supported by the observation that CD15+ MDSC depletion (anti-CD15 beads) from PB mononuclear cells significantly improved T cell IFN γ production, and that the addition of positively selected CD15+CD33+ cells to isolated patient T cells restored T cell suppression (20).

Similar to what we observed in murine tumor models, sunitinib treatment of mRCC patients dramatically reduced the number of MDSCs (CD33+CD15+HLA-DR⁻ and CD15-CD33+HLA-DR⁻) in the PB (Day 28 of cycle 1) (20). Analysis of patients receiving multiple cycles of sunitinib suggests that maximal reduction in MDSC numbers occurs after the 2nd cycle and remains depressed even after the 4th cycle, although there is some recovery in MDSC levels at this time (Finke unpublished). This reduction in PB MDSCs correlated with a significant increase in T-cell IFN γ production after *in vitro* stimulation with anti-CD3/anti-CD28 antibodies (r=-0.66, p=.03) (20). An additional report in RCC patients showed that the percentage of CD14+HLA-DR neg/low MDSC was increased compared to normal donors which was reduced by sunitinib treatment. Interestingly the reduced frequency of dendritic cell subsets, myeloid-DC-1 (MDC-1) and myeloid-DC-2 (MDC-2), noted in RCC patients was restored to normal baseline levels with sunitinib treatment and the high MDC-1 frequency correlated with tumor shrinkage (32). These finding suggest that sunitinib monotherapy in RCC patients can reduce immune suppression there by providing a rationale for combining sunitinib with immunotherapy.

Evidence of MDSC resistance in some RCC patients receiving sunitinib is suggested by the persistence of intratumoral MDSCs and T cell suppression..

Sunitinib treatment of metastatic patients with prior resection of primary tumors resulted in reduced MDSC frequency and restored T cell IFN γ response in PB mononuclear cells (20). However, the impact of sunitinib on the persistence of intratumoral MDSCs and T cell function is not possible in this patient population. A phase II trial of neoadjuvant sunitinib by Rini, et al., (manuscript in preparation) has involved treating patients with sunitinib where the primary RCC tumors were not amenable to resection. Neoadjuvant sunitinib led to downsizing/downstaging of primary tumors, which allowed resection in over 40% of

initially unresectable, primary, RCC tumors. Although not complete, an early analysis of tumors from neoadjuvant patients compared to untreated tumors shows variability in the ability of sunitinib to reduce MDSC levels and restore T cell IFN γ production within the tumor bed, a finding similar to those observed in our murine tumor models. Of the neoadjuvant tumors examined post-sunitinib treatment, (d 9-25) 3/8 had very low levels of MDSCs (0.7%, 2% and 0.9% CD33+HLA-Dr-) compared to MDSC levels in untreated tumors (5.9% MDSC) and significant T cell IFN γ production (27%, 15%, 10% IFN γ +) comparable to healthy donor PB T cells (18+/-1.5%, n=21). However, 5/8 patients showed suppressed T cell function (3.0%, 3.5%, 1.0%, 1.5% and 2% IFN γ +) similar to tumor-derived T cells from untreated RCC patients (8.7+/-1.2%, n=19). Of these 5 tumors, MDSC levels were available from 3 samples and all of the samples had high MDSC levels (4.9%, 10.2% and 4.2%), similar to untreated RCC patients.

Whether local production of GM-CSF is responsible for the persistence of MDSCs in some of the neoadjuvant patients is not yet established; however, preliminary data from short-term cultures (1-3 passages) of freshly isolated RCCs (n=15) along with several established RCC lines (n= 6) showed that tumors can produce sufficient amounts of GM-CSF (887.9+/-307.7 pg/ml) to protect MDSCs *in vitro* from sunitinib-induced apoptosis ((19) and Ko, et al., unpublished). Moreover, the concentration of GM-CSF detected in tumor cell line supernatants was sufficient to induce pSTAT5 in MDSCs isolated from the PB of RCC patients. A role for GM-CSF in promoting MDSC accumulation in sunitinib- treated TB hosts is supported by studies implicating GM-CSF in MDSC expansion (33) and by the observations that vaccine strategies employing high-dose GM-CSF promoted MDSC expansion and reduction in T cell immune responses (34,35).

Tumor and MDSC production of proangiogenic proteins may contribute to sunitinib resistance in RCC patients

MDSCs are known to promote angiogenesis and tumor progression via a STAT3-dependent pathway (12,13). In fact MDSCs producing Bv8 (VEGF homologue prokineticin-2) appear to promote resistance to anti-VEGF antibody treatment. However, there is little information on the impact of proangiogenic products on sunitinib resistance in RCC patients with the exception of IL-8 (36). Immunostaining of pretreatment human RCC tissue revealed that high IL-8 staining was associated with sunitinib non-responders, while low IL-8 staining was associated with clinical response. Moreover, in an RCC xenograft model, treatment with sunitinib mimicked the resistance observed in humans and co-treatment with anti-IL-8 antibody restored sensitivity of TB mice to sunitinib (36).

Our preliminary analysis of tumor tissue lysates show an apparent increase in expression of proangiogenic proteins (MMP9, MMP8 and IL-8) in neoadjuvant sunitinib-treated patients with persistent high MDSC levels (3/5 patients), relative to levels detected in neoadjuvant patients with low MDSC levels (n=2) and even to the levels detected in the control tumors (n=7). Although greater numbers are needed, the increase in tumor tissue levels of MMP9, MMP8 and IL-8 in the 3 neoadjuvant patients where MDSCs persisted suggest that MDSCs contribute to the production of an acquired alternate-type proangiogenic profile that may be enhanced by sunitinib treatment. Indeed, using MDSC subsets isolated from human RCCs via fluorescence-activated cell sorter (FACS), our PPA analysis of 50 angiogenic proteins demonstrated that n-MDSCs expressed high levels of MMP9, MMP8 and to a lesser extent IL-8 when compared to the other two subsets. Clearly, additional neoadjuvant tumor samples are needed to determine whether there are two subsets of RCC patients, one sensitive to sunitinib with low MDSC numbers and low expression of proangiogenic proteins (MMP9, MMP8, IL-8) and another resistant to sunitinib with persistent levels of MDSCs and elevated levels of proangiogenic proteins.

While IL-8 likely contributes to sunitinib resistance, its mechanism of action remains unclear. Interestingly, we have shown that increased plasma levels of IL-8 in mRCC patients during sunitinib treatment correlated with a significant decrease in progression-free survival (PFS) relative to patients where the IL-8 levels decreased or were unchanged from pre-treatment values (Varella, L., et al., manuscript in preparation). One potential explanation for the inverse correlation between plasma IL-8 levels and PFS is that enhanced IL-8 production in the tumors promotes accumulation of MDSC, thus leading to enhanced alternative proangiogenic pathways (MMP9/MMP8/IL8), thereby enhancing tumor growth. IL-8 is a chemoattractant for neutrophils, and likely n-MDSCs, that binds to the chemokine receptor CXCR2 (37). We have shown that over 53% of n-MDSCs and 20% lin-/m-MDSCs infiltrating RCCs express this receptor. Since IL-8 is a chemokine with potent proangiogenic activity, the up-regulation of IL-8 may induce proangiogenic pathways that allow the tumor to escape the anti-angiogenic activity of sunitinib-mediated VEGFR blockade. Additional studies are needed to test whether sunitinib resistance in RCC patients is linked to increased numbers of intratumoral MDSCs and increased expression of proangiogenic proteins, such as MMP9 and IL-8. In addition, the mechanism behind selective persistence and protection of MDSC in resistant RCC tumors compared to the peripheral blood requires further investigation.

It will be of interest to determine whether MDSCs from blood and tumors of RCC patients promote angiogenic activity in the RCC xenograft model. However, we have shown that incubation of normal donor blood with tumor-conditioned media (TCM) from melanoma and RCC lines, activates neutrophils and monocytes to display a greater ability to suppress T cell production of IFN γ when compared to either naive neutrophils or monocytes (Ko, et al., ASCO abstract 2010, Ko unpublished data). Of most relevance, we showed that neutrophils and monocytes activated by RCC/Melanoma TCM, significantly increased the number of peri-tumoral blood vessels when implanted with a melanoma line (A375) into nude mice. Neutrophils and monocytes isolated from normal donors, but not exposed to TCM, failed to promote blood vessel formation in the xenograft model (data not shown).

Summary

Our findings and those of others implicate the involvement of MDSC in tumor escape via immune suppression as well as anti-angiogenic drug resistance. Understanding the mechanisms which are involved in tumor resistant to sunitinib, including defining the contribution of MDSCs in this process, may provide new strategies for reducing resistance to this TKI and possibly other TKIs.

Acknowledgments

Supported by Pfizer and RO1 CA150959-2

References

1. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. *Br J Cancer*. 2006; 94:614–619. [PubMed: 16465192]
2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med*. 2007; 356:115–124. [PubMed: 17215529]
3. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. *Clin Cancer Res*. 2007; 13:680s–684s. [PubMed: 17255293]
4. Roskoski R Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. *Biochem Biophys Res Commun*. 2007; 356:323–328. [PubMed: 17367763]

5. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. *Nat Rev Drug Discov.* 2007; 6:734–745. [PubMed: 17690708]
6. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. *Cancer Res.* 2003; 63:4009–4016. [PubMed: 12873999]
7. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. *Cancer Res.* 2009; 69:2506–2513. [PubMed: 19244102]
8. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. *Nat Rev Immunol.* 2004; 4:941–952. [PubMed: 15573129]
9. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. *Nat Med.* 1996; 2:1096–1103. [PubMed: 8837607]
10. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. *Immunol Rev.* 2008; 222:162–179. [PubMed: 18364001]
11. Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. *Clin Cancer Res.* 2007; 13:5243–5248. [PubMed: 17875751]
12. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. *J Clin Invest.* 2008; 118:3367–3377. [PubMed: 18776941]
13. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC. Expansion of myeloid immune suppressor Gr⁺CD11b⁺ cells in tumor-bearing host directly promotes tumor angiogenesis. *Cancer Cell.* 2004; 6:409–421. [PubMed: 15488763]
14. Crawford Y, Ferrara N. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. *Trends Pharmacol Sci.* 2009; 30:624–630. [PubMed: 19836845]
15. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP, Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b⁺Gr1⁺ myeloid cells. *Nat Biotechnol.* 2007; 25:911–920. [PubMed: 17664940]
16. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, Geilich M, Winkels G, Traggiai E, Casati A, Grassi F, Bronte V. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. *Eur J Immunol.* 40:22–35. [PubMed: 19941314]
17. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. *Cancer Immunol Immunother.* 59:1593–1600. [PubMed: 20414655]
18. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R, Bukowski R. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. *Clin Cancer Res.* 2008; 14:6674–6682. [PubMed: 18927310]
19. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Finke JH, Cohen PA. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. *Cancer Res.* 70:3526–3536. [PubMed: 20406969]
20. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. *Clin Cancer Res.* 2009; 15:2148–2157. [PubMed: 19276286]
21. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, Schwartz M, Divino CM, Pan PY, Chen SH. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. *Cancer Res.* 2009; 69:2514–2522. [PubMed: 19276342]
22. Abe F, Younos I, Westphal S, Samson H, Scholar E, Dafferner A, Hoke TA, Talmadge JE. Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice. *Int Immunopharmacol.* 10:140–145. [PubMed: 19833232]

23. Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, Ko JS, Cohen PA, Finke JH, Storkus WJ. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. *Int J Cancer*.
24. Kujawski M, Zhang C, Herrmann A, Reckamp K, Scuto A, Jensen M, Deng J, Forman S, Figlin R, Yu H. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. *Cancer Res*. 70:9599–9610. [PubMed: 21118964]
25. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. *Nat Rev Immunol*. 2007; 7:41–51. [PubMed: 17186030]
26. Cohen PA, Koski GK, Czerniecki BJ, Bunting KD, Fu XY, Wang Z, Zhang WJ, Carter CS, Awad M, Distel CA, Nagem H, Paustian CC, Johnson TD, Tisdale JF, Shu S. STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. *Blood*. 2008; 112:1832–1843. [PubMed: 18577706]
27. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity and subset definition. *Curr Opin Immunol*. 22:238–244. [PubMed: 20171075]
28. Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H, Yancey D, Dahm P, Vieweg J. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. *Clin Cancer Res*. 2008; 14:8270–8278. [PubMed: 19088044]
29. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. *Cancer Res*. 2009; 69:1553–1560. [PubMed: 19201693]
30. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, Mier J, Ochoa AC. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. *Cancer Res*. 2005; 65:3044–3048. [PubMed: 15833831]
31. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. *Cancer Res*. 2001; 61:4756–4760. [PubMed: 11406548]
32. van Cruijssen H, van der Veldt AA, Vroeling L, Oosterhoff D, Broxterman HJ, Scheper RJ, Giaccone G, Haanen JB, van den Eertwegh AJ, Boven E, Hoekman K, de Gruijl TD. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. *Clin Cancer Res*. 2008; 14:5884–5892. [PubMed: 18794101]
33. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. *Nat Rev Immunol*. 2009; 9:162–174. [PubMed: 19197294]
34. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. *J Clin Oncol*. 2007; 25:2546–2553. [PubMed: 17577033]
35. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. *Cancer Res*. 2004; 64:6337–6343. [PubMed: 15342423]
36. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, Kahnoski R, Futreal PA, Furge KA, Teh BT. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. *Cancer Res*. 70:1063–1071. [PubMed: 20103651]
37. Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. *J Immunol*. 2005; 175:5351–5357. [PubMed: 16210641]

Table 1

Immunomodulatory Activity of Sunitinib

Murine Model	Reduced MDSC (Gr1+CD11b+) (Spleen Tumor)	Restored T cell Function (Spleen Tumor LN)	Improved Immunotherapy	Reference
Renca	Yes	Yes	ND	(7,19)
CT26	Yes	Yes	ND	(19)
MCA26	Yes	Yes	Adv.mIL-12 + 4-1BBL	(21)
4T1	Yes	Yes	ND	(19)
Her2/neu induced Mammary Tumor (FVB-neuN)	Yes	Yes	ND	(22)
B16^{OVA}	Yes	ND	Yes	Adoptive CD8+ T cells (24)
B16.OVA	Yes	Yes	OVA peptide pulsed DC Vaccine	(23)

Human Tumor	Phenotype of Reduced MDSC	Restored T cell Function	Reference
Metastatic RCC	CD33+HLADr-CD15+/-CD14-	PBMC (IFN γ)	(20)
Metastatic RCC	CD14+HLADr-/low CD15+/-CD14-	ND	(32)
Neoadjuvant RCC	CD33+HLADr-CD15+/-CD14-	T cells (IFN γ)	Finke Unpublished